Danaher Corporation's Stock Performance: Danaher Corporation (NYSE:DHR) has been included in the list of the 11 Best Rebound Stocks to Buy according to hedge funds, despite a year-to-date decline in share price. Wells Fargo recently lowered its price target for the company from $210 to $205 while maintaining an 'Equal Weight' rating after a solid EPS beat and positive guidance revision.
Growth Prospects: Analysts are optimistic about Danaher's recovery, particularly due to strength in its Bioprocess segment and expected improvements in the Life Science segment. Positive trends in the Pharma segment and growth momentum in China further enhance the company's investment appeal.
DHR
$222.63+Infinity%1D
Analyst Views on DHR
Wall Street analysts forecast DHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DHR is 246.09 USD with a low forecast of 220.00 USD and a high forecast of 270.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
Wall Street analysts forecast DHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DHR is 246.09 USD with a low forecast of 220.00 USD and a high forecast of 270.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
3 Hold
0 Sell
Strong Buy
Current: 224.700
Low
220.00
Averages
246.09
High
270.00
Current: 224.700
Low
220.00
Averages
246.09
High
270.00
BofA
Buy
maintain
$250 -> $265
2025-12-15
New
Reason
BofA
Price Target
$250 -> $265
2025-12-15
New
maintain
Buy
Reason
BofA raised the firm's price target on Danaher to $265 from $250 and keeps a Buy rating on the shares. The firm is updating it price targets for Life Sciences & Diagnostic Tools stocks under its coverage, the analyst tells investors. Headwinds are expected to fade, and markets are expected to normalize in 2026, firm adds. The firm believes the biggest upside for the sector will be a return to spending by Biopharma, leading BofA to favor companies with higher exposure to research and development.
Wells Fargo
Equal Weight
maintain
$230 -> $240
2025-12-15
New
Reason
Wells Fargo
Price Target
$230 -> $240
2025-12-15
New
maintain
Equal Weight
Reason
Wells Fargo raised the firm's price target on Danaher to $240 from $230 and keeps an Equal Weight rating on the shares. With U.S. policy uncertainty lifting on Pharma and forward growth expectations already well-anchored with room for upside, the firm likes the setup for Tools.
Goldman Sachs
initiated
$265
2025-12-09
Reason
Goldman Sachs
Price Target
$265
2025-12-09
initiated
Reason
Goldman Sachs initiated coverage of Danaher with a Buy rating and $265 price target. The firm rolled out coverage of the large cap life science tools stocks with the expectation that they will eventually return to their historic market growth rate of 5%. However, some end markets will recover faster than others, the analyst tells investors in a research note. Goldman is taking a more cautious view on the timing of the drug discovery end market recovery and believes the recent uptick in biotech funding is largely focused on later stage assets. It also takes a more cautious stance on U.S. academic and government spending. The firm says investors need to be selective, and likes exposure to commercialized biopharma manufacturing, later stage research, and industrials.
Wells Fargo
Equal Weight
maintain
$205 -> $230
2025-10-23
Reason
Wells Fargo
Price Target
$205 -> $230
2025-10-23
maintain
Equal Weight
Reason
Wells Fargo raised the firm's price target on Danaher to $230 from $205 and keeps an Equal Weight rating on the shares. The firm notes the company reaffirmed its 2025 EPS guide, despite lowering Q4 organic growth. Initial 2026 outlook calls for positive high single digit EPS growth, even at low-end of +3%-6% core revenue growth, which seems to leave room for upside on Life Sci, OP margin and capital allocation fronts.
About DHR
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
